Can Blood Cause Positive Fetal Fibronectin?
Yes, vaginal blood contamination can cause false-positive fetal fibronectin (fFN) test results, but the clinical significance depends on the degree of contamination and the specific clinical context.
Evidence on Blood Contamination Effects
Laboratory Studies on Blood Interference
Blood contamination directly causes false-positive fFN results in a dose-dependent manner: Laboratory testing demonstrated that fFN tests were positive in only 8% of samples with 0.5% blood contamination, but this increased dramatically to 67% with 1% contamination and 100% with 10% contamination 1.
Blood samples from both pregnant and non-pregnant women test positive for fFN: All blood samples from pregnant women contained detectable fFN, and surprisingly, blood samples from non-pregnant women also tested positive, likely due to cross-reactivity of the FDC-6 monoclonal antibody with hepatic fibronectin 2.
Vaginal bleeding invalidates test interpretation: When blood is visible in vaginal samples, the fFN test results cannot be reliably interpreted due to the presence of fibronectin in maternal blood 3.
Clinical Studies on Bleeding and Test Performance
Vaginal bleeding paradoxically reduces false-positive rates in symptomatic women: In a large study of 708 symptomatic women with threatened preterm labor, vaginal bleeding was associated with a significantly lower risk of false-positive results (odds ratio 0.22,95% CI 0.12-0.39), though it increased the proportion of positive fFN results overall 4.
Vaginal bleeding significantly increases invalid test results: The same study found that vaginal bleeding was the only external factor significantly associated with invalid fFN tests (odds ratio 4.5,95% CI 1.7-12) 4.
One recent study contradicts the blood interference concern: A 2020 retrospective cohort study reported that blood present on the fFN sample did not affect test reliability, with the negative predictive value remaining 100% 5. However, this single study conflicts with multiple earlier investigations demonstrating blood interference.
Clinical Implications and Testing Criteria
When fFN Testing Should NOT Be Performed
ACOG guidelines specify that fFN testing requires intact amniotic membranes and minimal cervical dilatation 6. While these guidelines do not explicitly mention blood contamination as a contraindication, the requirement for intact membranes implicitly excludes many bleeding scenarios.
Interpretation Algorithm
For symptomatic women with threatened preterm labor:
If minimal blood spotting is present: The test may still be performed, as clinical studies suggest the negative predictive value remains high, though the risk of invalid results increases 4, 5.
If moderate to heavy vaginal bleeding is present: Defer fFN testing, as blood contamination >1% causes false-positive results in the majority of cases 1.
If the test is positive in the presence of any vaginal bleeding: Interpret with extreme caution and do not rely on this result alone for clinical decision-making, as it may represent blood contamination rather than true fFN elevation 2, 3.
If the test is negative despite vaginal bleeding: The negative result retains high predictive value for ruling out imminent preterm delivery within 7 days 4, 5.
Key Clinical Pitfalls
Do not assume all positive fFN results in bleeding patients are true positives: Blood contamination as low as 1% can cause false-positive results in two-thirds of samples 1.
Invalid results are more common with bleeding: Vaginal bleeding increases the likelihood of technically invalid tests that cannot be interpreted 4.
The mechanism of false-positives is cross-reactivity: The FDC-6 monoclonal antibody used in fFN assays cross-reacts with hepatic fibronectin present in maternal blood, not just fetal fibronectin 2.
Negative results remain clinically useful: Even in the presence of blood contamination, a negative fFN test maintains excellent negative predictive value for ruling out delivery within 7 days 4, 5.
Practical Recommendation
In clinical practice, avoid fFN testing when moderate to heavy vaginal bleeding is present. If minimal spotting is present and the test is performed, prioritize the negative predictive value (which remains robust) over positive results (which may be falsely elevated due to blood contamination). When fFN is positive in the setting of any vaginal bleeding, correlation with cervical length measurement by transvaginal ultrasound is essential for accurate risk stratification 6, 4.